Bemnifosbuvir

N/A

Report date: 2025/12/23 17:06:12
NME

Base Information

Drug NameBemnifosbuvir
Drug Alias NameAT-527RO-7496998RG-6422
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsRNA-directed RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyLiver Cirrhosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAtea Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche AgAtea Pharmaceuticals IncF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyLiver Cirrhosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A